One such agent is pemigatinib, a selective fibroblast growth factor receptor 2 (FGFR2) inhibitor, approved for patients with FGFR2 gene fusions or rearrangements, a genomic alteration observed in a subset of intrahepatic cholangiocarcinoma cases. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.